Enfortumab vedotin–related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: June 12, 2024

Enfortumab vedotin (EV) is an antibody drug conjugate approved for advanced urothelial cancer, consisting of a monomethyl auristatin E payload linked to human monoclonal targeting nectin-4. No validated biomarker predictive or correlated with response exists EV. Cutaneous toxicity among the most common EV-related toxicities and typically emerges in early cycles. This retrospective experience patients cancer treated EV monotherapy evaluated whether cutaneous improved outcomes including progression-free (PFS) overall (OS) survival rate (ORR).

Language: Английский

---

Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient

American Society of Clinical Oncology Educational Book, Journal Year: 2024, Volume and Issue: 44(3)

Published: May 21, 2024

The standard treatment paradigm for muscle invasive bladder cancer has been neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. However, efforts are ongoing to personalize incorporating biomarkers better guide selection. In addition, preservation strategies aimed at avoiding cystectomy in well-selected patients. Similarly, the metastatic urothelial space, frontline option of platinum-based changed with availability data from EV-302 trial, making combination enfortumab vedotin (EV) and pembrolizumab preferred first-line option. Here, we examine optimization intensity sequencing, focusing on challenges opportunities associated EV/pembrolizumab therapy, including managing toxicities exploring alternative dosing approaches. Together, these articles provide a comprehensive overview contemporary management, highlighting importance individualized approaches, research, multidisciplinary collaboration improve patient outcomes this complex disease landscape.

Language: Английский

---

Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence

Life Sciences, Journal Year: 2024, Volume and Issue: 352, P. 122910 - 122910

Published: Sept. 1, 2024

Language: Английский

---

Case report: Enfortumab vedotin induced refractory DKA and multi organ failure – a rare fatal adverse event

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Feb. 15, 2024

There are very few therapeutic options to treat patients with locally advanced or metastatic Urothelial Cancer (UC). Enfortumab vedotin (EV) was recently approved by the FDA and has become a new option for previously managed conventional treatments. Despite its efficacy, EV carries potential infrequent yet severe adverse effects. In this report, we present case of patient undergoing treatment urothelial carcinoma who developed refractory diabetic ketoacidosis (DKA) unresponsive escalating insulin doses necessitating continuous renal replacement therapy. While DKA resolved, eventually succumbed progressive maculopapular skin rash, liver failure, respiratory failure. Additionally, study delves into review cases EV-induced in literature, shedding light on similarities profiles, timelines effects strategies employed manage ensuing complications.

Language: Английский

---

Desquamative extravasation reaction secondary to enfortumab vedotin

JAAD Case Reports, Journal Year: 2024, Volume and Issue: 46, P. 15 - 17

Published: Feb. 13, 2024

Language: Английский

---

Antibody–Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data

Current Oncology, Journal Year: 2024, Volume and Issue: 31(4), P. 2316 - 2327

Published: April 19, 2024

The treatment landscape of genitourinary cancers has significantly evolved over the past few years. Renal cell carcinoma, bladder cancer, and prostate cancer are most common malignancies. Recent advancements have produced new targeted therapies, particularly antibody–drug conjugates (ADCs), due to a better understanding underlying oncogenic factors molecular mechanisms involved. ADCs function as ‘drug delivery into tumor’ system. They composed an antigen-directed antibody linked cytotoxic drug that releases components after binding tumor cell’s surface antigen. been proven be extremely promising in several types. For GU cancers, this novel only benefited patients with metastatic urothelial (mUC). rest paradigm does not any FDA-approved ADC options available yet. In study, we thoroughly completed narrative review current literature summarized preclinical studies clinical trials evaluated utility, activity, toxicity prospects development, ongoing trials. Prospective trials, retrospective studies, case reports, scoping reviews were included.

Language: Английский

---

Antibody-drug conjugates: A review of cutaneous adverse effects

Journal of the American Academy of Dermatology, Journal Year: 2024, Volume and Issue: 91(5), P. 922 - 931

Published: July 22, 2024

Language: Английский

---

Diagnosis and Management of Skin Toxicities in Systemic Treatment of Genitourinary Cancers

Cancers, Journal Year: 2025, Volume and Issue: 17(2), P. 251 - 251

Published: Jan. 14, 2025

The landscape of available therapeutic options for treatment genitourinary (GU) cancers is expanding dramatically. Many these treatments have distinct, sometimes severe, skin toxicities including morbilliform, bullous, pustular, lichenoid, eczematous, psoriasiform, and palmoplantar eruptions. Pruritus pigmentation changes also been noted. This review aims to synthesize dermatologic events observed with antibody drug conjugates, poly (ADP-ribose) polymerase (PARP) inhibitors, androgen receptor pathway tyrosine kinase immune checkpoint the combination agents used GU cancers. It provides a guide on diagnosis initial management rashes medical oncologists.

Language: Английский

---

Mechanisms and optimization strategies for the occurrence of antibody-drug conjugate toxicity

Theoretical and Natural Science, Journal Year: 2025, Volume and Issue: 69(1), P. 177 - 182

Published: Jan. 15, 2025

Antibody-drug conjugates (ADCs) have emerged as a promising class of targeted cancer therapies, with 13 ADCs approved by the FDA and over 140 undergoing clinical research. are designed to enhance selective delivery cytotoxic drugs tumor cells through high-affinity monoclonal antibodies (mAbs), improving therapeutic index drug. Despite their potential, face significant challenges related toxicity, including hematologic, ocular, skin, neurological side effects, which limit application. This review provides an in-depth analysis mechanisms underlying ADC includes both off-target effects that can damage normal tissues. Strategies for optimizing safety, such antibody structure, effector molecules, linkers, combination discussed. The emphasizes need continued research address these reduce toxicity while enhancing efficacy ADCs, paving way development safer more effective next-generation drugs.

Language: Английский

---

Impact of initial relative dose intensity on tumor response and survival outcomes in enfortumab vedotin monotherapy for previously treated advanced urothelial carcinoma: A real-world analysis from a multicenter study

Clinical Genitourinary Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 102326 - 102326

Published: March 1, 2025

Language: Английский

---